Clinical efficacy of autologous stem cell transplantation for the treatment of patients with type 2 diabetes mellitus: a meta-analysis

Wang, Zheng-Xu; Cao, Jinglin; Li, Duo; Zhang, Xiaoyan; Liu, Jinlong; Li, Junli; Wang, Min; Xu, Beilei; Wang, Haibo

doi:10.1016/j.jcyt.2015.02.014

Cited by 29 publications

(24 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our findings showed no significant differences of FPG at the end of the follow-up in the included trials, which is inconsistent with the previous meta-analysis [ 7 ]. However, this meta-analysis included Chinese studies published in Chinese, and this study did not assess the quality of the studies included.…”

Section: Discussioncontrasting

confidence: 99%

“…A previous meta-analysis in 2016 included seven studies involving 224 patients, investigating stem cell therapy on T2DM for 6 months, and suggested that HbA1c and C-peptide levels were significantly reduced compared with baseline levels [ 6 ]. Another meta-analysis published in 2015 including 15 trials, and 497 patients showed a significant decrease in the daily insulin requirement at 3, 6, 9, and 12 months [ 7 ], but the FPG and C-peptide values did not change significantly. However, the previously published studies included some limitations such as limited numbers of trials or limited trials in the subgroup analysis, inclusion of participants with varying degrees of glycemic control at baseline, or relatively small sample sizes.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of Autologous Bone Marrow Mononuclear Cell Transplantation Therapy for Type 2 Diabetes Mellitus: An Updated Meta-Analysis

Guo

et al. 2019

Diabetes Ther

View full text Add to dashboard Cite

Introduction Studies of the effects of stem cell therapy on type 2 diabetes mellitus (T2DM) have not reached consistent results. Our meta-analysis aimed to systematically evaluate the efficacy of autologous bone marrow-derived stem cells (ABM-MNCs) on T2DM. Methods We systematically searched PubMed, EMBASE, Web of Science, and the Cochrane Library for studies published between 1980 and May 2018. Two researchers screened the literature independently following the inclusion and exclusion criteria. Meta-analysis of the pooled standard mean difference (SMD) with 95% confidence interval (CI) was calculated based on either a fixed- or random-effects model. Results We identified six studies with 206 participants investigating the effects of autologous bone marrow stem cell therapy on T2DM after screening 102 studies found after the initial search. According to the pooled estimates, compared with the control group, after 12-month follow-up the ABM-MNC therapy group had a lower level of HbA1c (MD, − 1.18; 95% CI, − 1.40 to 0.95) and lower required insulin dose (MD, − 2.05; 95% CI, − 3.55 to − 0.55). HbA1c decreased after ABM-MNC therapy compared with before (12 months: MD, − 1.22; 95% CI, − 1.43 to − 1.0). We also observed a significant decrease in insulin requirement after 3-, 6-, 9-, and 12-month follow-up in the ABM-MNC group, respectively. Conclusion Autologous stem cell therapy showed a beneficial effect on T2DM.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Efficacy of Autologous Bone Marrow Mononuclear Cell Transplantation Therapy for Type 2 Diabetes Mellitus: An Updated Meta-Analysis

Guo

et al. 2019

Diabetes Ther

View full text Add to dashboard Cite

show abstract

“…The idea of giving bone marrow cells seems to work and achieve similar results to what was reported by other groups (26)(27)(28)(29)(30). The important part is that this could be done in a simple set up where the patient can be hospitalized for a single night and discharged the second day to be followed up and monitored.…”

Section: Discussionsupporting

confidence: 64%

“…Giving BM-MNSCs is not a new idea. As discussed earlier, several groups have shown that we can use the BM-MNSCs to stop or taper the manifestations, complications and possibly halt T2D for a variable period of time (26)(27)(28)(29)(30).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Bone marrow derived stem cell therapy for type 2 diabetes mellitus

Wehbe¹,

Chahine²,

Sissi³

et al. 2016

Stem Cell Investig.

View full text Add to dashboard Cite

In this study, 6 patients with type 2 diabetes (T2D) underwent autologous bone marrow mononuclear stem cell (BM-MNSC) infusion into the celiac and superior mesenteric arteries without pretreatment with any myeloablative or immune-suppressive therapy. Five of 6 (83%) showed normalization of their fasting glucose and the glycosylated hemoglobin (HbA1C) with significant reduction of their medication requirements. The HbA1C dropped on average 2.2 points. The three patients with diabetic complications showed improvement or stabilization and most patients reported improved energy and stamina. The durations of response varied between 6 months and 2 years. No patients had any significant adverse effects.

show abstract

Resveratrol increases stem cell function in the treatment of damaged pancreas

Chen

Kuo

Day

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Pancreatic damage results in insufficient insulin secretion, leading to type 1 diabetes. Stem cell-based therapy has recently shown potential in the treatment of type 1 diabetes. Resveratrol supplementation has demonstrated a beneficial effect in treating diabetes. This study investigates if adipose-derived stem cells (ADSC), preconditioned with resveratrol, show better effects on experimental diabetic animals. Wistar rats were randomly divided into four groups including sham (normal rats), DM (diabetic rats induced by SZT injection), DM+ADSC (DM rats with receiving autologous ADSC transplantation) and DM+R-ADSC (DM rats receiving resveratrol preconditioned ADSC). The experimental results show that SZT induced pancreatic damage (DM group), including reduction of islet size, fibrosis pathway activation, survival signaling suppression, and apoptotic pathway expression, lead to serum glucose elevation. Autologous ADSC (DM+ADSC group) transplantation shows improvement in the above observations in DM rats.Furthermore, ADSC precondition with resveratrol (DM+R-ADSC group) reveals significant improvement in the above pathological observations over both DM and DM+ADSC groups. We found that ADSC precondition with resveratrol increases the survival marker p-Akt expression, leading to enhanced ADSC viability. This

show abstract

Clinical efficacy of autologous stem cell transplantation for the treatment of patients with type 2 diabetes mellitus: a meta-analysis

Cited by 29 publications

References 32 publications

Efficacy of Autologous Bone Marrow Mononuclear Cell Transplantation Therapy for Type 2 Diabetes Mellitus: An Updated Meta-Analysis

Efficacy of Autologous Bone Marrow Mononuclear Cell Transplantation Therapy for Type 2 Diabetes Mellitus: An Updated Meta-Analysis

Bone marrow derived stem cell therapy for type 2 diabetes mellitus

Resveratrol increases stem cell function in the treatment of damaged pancreas

Contact Info

Product

Resources

About